This year’s congress of the European Society for Medical Oncology , which took place in Berlin from October 17 to 21, 2025, offered an impressive variety of topics on numerous tumor entities and therapeutic approaches. These were presented in various formats. These included interactive formats such as the “Challenge your Expert” sessions, in which the audience could ask questions, make critical comments and confront the experts with practical challenges. In the “Challenge your Expert-Session-Gynae-Cancers”, David M. Gershenson presented new therapeutic approaches for low-grade serous ovarian cancer (LGSOC). His presentation focused on the development of innovative combination therapies that go beyond the current standards of chemotherapy and hormone therapy and open up new horizons for the treatment of this rare tumor entity.
Autoren
- Dr. oec. Odile Schwarz-Herion
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
- BRAF
- Chemotherapy + Letrozole versus Letrozole
- Combination therapy
- Hormonal therapy
- international Phase II/III study GOG 0281
- Johns Hopkins study
- KRAS
- Low grade serous ovarian carcinoma (LGSOC)
- Maintenance therapy
- MAP kinase signaling pathway mutation
- MD Anderson Cancer Center (MDACC)
- Mixed tumors LGSOC and HGSOC
- molecular precision medicine
- NRAS
You May Also Like
- Why lipoprotein(a) is the biggest therapeutic vacuum in cardiology
Lp(a): The underestimated risk factor before the turning point
- Modern system therapeutics for hidradenitis suppurativa
Immunological dysregulation in the sights of several biologics and “small molecules”
- Perimenopausal depression, PMDS and tokophobia
Psychosomatics and mental health in gynecology
- Proteins in wound healing
Do special amino acids lead to success?
- Plastic surgery and reconstructive microsurgery for DFS
Functional limb preservation between infection control, vascular medicine and resurfacing
- Polycystic ovary syndrome 2025/2026
New pathophysiology, updated diagnostics and the age of incretin mimetics
- Heart failure and type 2 diabetes
Oral semaglutide and cardiac decompensation in type 2 diabetes
- Atopic dermatitis as a door opener for an atopic cascade?